JP2024520395A - 置換される縮合二環式大環状化合物および関連のある治療方法 - Google Patents

置換される縮合二環式大環状化合物および関連のある治療方法 Download PDF

Info

Publication number
JP2024520395A
JP2024520395A JP2023572622A JP2023572622A JP2024520395A JP 2024520395 A JP2024520395 A JP 2024520395A JP 2023572622 A JP2023572622 A JP 2023572622A JP 2023572622 A JP2023572622 A JP 2023572622A JP 2024520395 A JP2024520395 A JP 2024520395A
Authority
JP
Japan
Prior art keywords
formula
another embodiment
alkyl
alkylene
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520395A5 (https=
Inventor
ヒューン，ホアン
ペニントン，ルイス，ディー．
チェ，ヨンギ
アクイラ，ブライアン，エム．
マッジ，インゴ，アンドレアス
フー，ユエン
ウッズ，ジェームズ，アール．
ライマー，ブライアン，ケネス
マーティン ベンツィエン，イョルグ
ウォード レーマン，ジョナサン
ヘール，マイケル，アール．
Original Assignee
アルカーメス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカーメス，インコーポレイテッド filed Critical アルカーメス，インコーポレイテッド
Publication of JP2024520395A publication Critical patent/JP2024520395A/ja
Publication of JP2024520395A5 publication Critical patent/JP2024520395A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023572622A 2021-05-26 2022-05-25 置換される縮合二環式大環状化合物および関連のある治療方法 Pending JP2024520395A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193243P 2021-05-26 2021-05-26
US63/193,243 2021-05-26
PCT/US2022/030839 WO2022251302A1 (en) 2021-05-26 2022-05-25 Substituted fused bicyclic macrocyclic compounds and related methods of treatment

Publications (2)

Publication Number Publication Date
JP2024520395A true JP2024520395A (ja) 2024-05-24
JP2024520395A5 JP2024520395A5 (https=) 2024-12-27

Family

ID=82851881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572622A Pending JP2024520395A (ja) 2021-05-26 2022-05-25 置換される縮合二環式大環状化合物および関連のある治療方法

Country Status (7)

Country Link
US (1) US20240182491A1 (https=)
EP (1) EP4347046A1 (https=)
JP (1) JP2024520395A (https=)
CN (1) CN117999265A (https=)
AU (1) AU2022281345A1 (https=)
CA (1) CA3219506A1 (https=)
WO (1) WO2022251302A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
US20240425521A1 (en) 2023-06-01 2024-12-26 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途
WO2026064378A1 (en) * 2024-09-18 2026-03-26 Vertex Pharmaceuticals Incorporated Macrocyclic sulfonamide modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019027003A1 (ja) * 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2020004536A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
PE20161064A1 (es) 2013-12-12 2016-10-28 Univ Tsukuba Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
WO2018053302A1 (en) * 2016-09-19 2018-03-22 Ensemble Therapeutics Corporation Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
US20200039998A1 (en) * 2016-12-19 2020-02-06 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN110627812B (zh) * 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
FI4065585T3 (fi) * 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
WO2022109117A1 (en) * 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2019027003A1 (ja) * 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
WO2020004536A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
US20240182491A1 (en) 2024-06-06
CN117999265A (zh) 2024-05-07
AU2022281345A1 (en) 2023-11-30
WO2022251302A1 (en) 2022-12-01
CA3219506A1 (en) 2022-12-01
EP4347046A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7580136B2 (ja) Ｊａｋ阻害剤化合物及びその使用
CN116615427B (zh) 被取代的大环化合物及相关治疗方法
JP6805220B2 (ja) 治療上活性な化合物およびそれらの使用方法
JP2024520395A (ja) 置換される縮合二環式大環状化合物および関連のある治療方法
CN107074852B (zh) ROR-γ的二氢吡咯并吡啶抑制剂
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
JP6517928B2 (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
CN104781254B (zh) 可作为激酶调节剂的经杂芳基取代的吡啶基化合物
JP5611959B2 (ja) Ｃ型肝炎ウイルス阻害剤
EP4329877B1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
TW202134229A (zh) 環烷基尿素衍生物
TW201639827A (zh) ＴＧＦ－β抑制劑
WO2010058846A1 (ja) ４，６-ジアミノニコチンアミド化合物
WO2016039408A1 (ja) 複素環化合物
JP7833486B2 (ja) 置換されるカルバメート大環状化合物および関連のある治療方法
AU2023288422A1 (en) Substituted fused bicyclic compounds and related methods of treatment
CN119730843A (zh) 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
JP2025521508A (ja) 置換ピロリジニル及びピペリジニル化合物並びに関連する治療方法
TW202542138A (zh) 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途
JP2025521504A (ja) 置換縮合二環式化合物および関連する治療方法
WO2025211415A1 (ja) 置換スルホンアミド化合物
HK40119559A (zh) 用於治疗与lpa受体活性相关的病症的化合物和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401